Allergan's Botox migraine should be well received, says Susquehanna Susquehanna is raising its forecast for Allergan's Botox sales following an investor lunch with an expert neurologist. The firm cited better than expected efficacy, the target market, and potential for a high level of acceptance and retention rates. Shares are Positive rated with a $93 price target.
News For AGN From The Last 14 Days
Check below for free stories on AGN the last two weeks.